Free press releases distribution network?

Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



U.S. MicroRNA Market to Reach $98.6 Million in 2015 Estimates Frost & Sullivan - Despite growing competition from new entrants, microRNA tool providers are witnessing extraordinary growth in their research product portfolios
U.S. MicroRNA Market to Reach $98.6 Million in 2015 Estimates Frost & Sullivan

 

PRZOOM - /newswire/ - Mountain View, CA, United States, 2009/05/04 - Despite growing competition from new entrants, microRNA tool providers are witnessing extraordinary growth in their research product portfolios.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

As evidence of the link between microRNAs and disease grows, the diagnostic and therapeutic potential of these molecules will remain the driving forces behind market expansion. MicroRNA research offers the capability of moving from bench to bedside faster than most research fields, as diagnostic tests have already emerged from this young field.

New analysis from Frost & Sullivan (drugdiscovery.frost.com), U.S. MicroRNA Markets, finds that the market earned revenues of over $20.3 million in 2008 and estimates this to reach $98.6 million in 2015.

If you are interested in a virtual brochure, which provides a brief synopsis of the research and a table of contents, then send an email to Christina Alfaro, Corporate Communications, at christina.alfaro[.]frost.com, with your full name, company name, title, telephone number, company email address, company website, city, state and country. Upon receipt of the above information, a brochure will be sent to you by email.

"The rapid discoveries linking microRNAs to various diseases have propelled the microRNA field as well as the market," explains Frost & Sullivan Research Analyst Christi Bird. "Additionally, the release of the first microRNA-based diagnostic test in 2008 eliminated some of the failure risk associated with this young field, which may prompt more researchers to enter the field."

Trends indicate that the adoption of microRNA research will continue to forge ahead rapidly over the next two years. All three major technologies used for microRNA research – microRNA microarrays, qRT-PCR, and functional analysis tools – are exhibiting high growth common to emerging markets for in-demand research fields.

While the young field continues to discover novel microRNAs in large numbers, it has already produced diagnostic results and demonstrated therapeutic potential. This condensed timeline from discovery to clinical importance has made the study of microRNAs extremely attractive and promising for both the academic researcher and diagnostic and therapeutic companies.

Although growth is on an upward trajectory, the size of the total market is relatively small compared to that of a mature market. Therefore, with increasing competition, revenues generated from microRNA portfolios do not match up to those attained by larger, more established markets.

"While the growth of the microRNA market is attractive to new competitors, the small total market size demonstrates that companies are not making huge profits in this market though some providers claim growth over 100 percent for their microRNA portfolios," continues Bird. "While companies are not seeing major revenues from the microRNA market compared to more mature portfolios, the strong growth forecast of the microRNA market predicts the total market size in 2015 to reach nearly five times that of the 2008 total."

Fierce competition in this space has propelled product differentiation to the forefront of marketing strategies. Researchers often exclusively focus on microRNAs important in their fields of research, thus specialized products containing the required microRNA targets may prove to be more attractive and economical options compared to comprehensive arrays. Vendors will gravitate toward more research-specific products, as more in-depth research is conducted and microRNAs are catalogued into particular fields.

Companies that are first to roll out such products will obtain increased visibility and improve brand recognition in specific fields. This will enable participants to garner a majority of the market share, especially in niche research areas. Companies that find a unique slot in the market hierarchy and continue to support technology innovation over the next few years can hope to attain higher revenues in the future.

U.S. MicroRNA Markets is part of the Drug Discovery and Clinical Diagnostics Growth Partnership Service program, which also includes research in the following markets: U.S. nucleic acid purification and isolation markets, U.S. qRT-PCR markets, U.S RNAi markets, and U.S. DNA microarray markets. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 31 offices on six continents.

U.S. MicroRNA Markets / N4DF

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


U.S. MicroRNA Market to Reach $98.6 Million in 2015 Estimates Frost & Sullivan

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Frost & Sullivan |
Contact: Christina Alfaro 
christina.alfaro[.]frost.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  BizJobs.com

Visit  La Bella Bakery Artisan Bakery Arizona

Visit  JobsWare.com







 
  ©2016 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today